medlatest Editorial

Stryker corporation is a big device player with orthopaedics, spine and neuro business to name three. Yet it’s European effort continues to result in falling share and disappointment. Recent management changes haven’t yet borne fruit, but the company is expecting better times ahead. While the medtech business can be a complicated affair, we suggest basic business principles still surely apply.

This week’s rant is less of a rant than an attempt to persuade companies of the value of the well written press release.

This week’s View From The Med is ready to read… unless you’re a tired ESC delegate wending your way home after another exhausting bash.

Ageing population, improved screening and new treatments will drive GI Endoscopy market in U.S.A

Meandering through the fields of news items that have sprung up this week we pause for reflection on whether product recalls and withdrawals are telling us products are getting to market too easily. We conclude they’re probably not, but we do think we need a bit more regulatory diligence.

Are the summer doldrums a good time to bury bad news or an opportunity to get your story to the top of the editor’s “hmmm interesting” list? We ponder this and other matters in our weekly View From The Med.

If you’re a fan Twitter’s great, but if you’re in any way busy it can become something of a sink for your time, which is why we’ve tried to help out by adding a customisable twitter feed page to medlatest. All you need to do is pick up to six feeds from our suggested list and each time you revisit our site…. there they are ready for your whistle-stop read.

News and views from the medtech industry, chewed over and spat out by our resident polemicist when he’s not involved in the Olympics (in a strictly observational capacity you understand)

The consequences of our distinct regulatory set-ups is that sometimes study information that drives indications for use one side of the pond is ignored on the other, despite the fact that it may have significant clinical consequences as seems to be the case with Stryker’s Wingspan Neurovascular Stent.

If you’re a medtech company with a new product or just a need for a higher profile, give it ten minutes and you’ll come up with stories that can become online assets. So why are we all so coy?

View From The Med is online now.

The 15th Medtech Investing Europe Conference takes place in September and as a Medlatest visitor you’re entitled to a helpful 40% discount. Find out more about the event in the full article.

You won’t see this feature very often… if at all… on other sites. At medlatest.com you can now select from our list of twitter feeds, the ones you’re interested in and bingo, as if by magic you have a customised medical device twitter page.

Is there enough newsworthy stuff happening in medtech to justify a weekly review? Oh yes.

View From The Med is online right now.

U.S Regulatory Agency the FDA is issuing guidelines under which it will give medical device makers feedback before they submit a product- or research-specific application.